Osteoporosis - secondary prevention including strontium ranelate
Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women.
Summary
This guidance replaces TA87 Osteoporosis - secondary prevention. Whether or not a postmenopausal woman who has had a bone fracture because of osteoporosis is offered treatment to prevent further fractures will depend on her age, her bone density and how many risk factors for fracture she has. Alen ...
Outcome of osteoporosis judicial review
The High Court has today (19 February 2009) ruled in favour of NICE on 2 of the 3 grounds brought against the Institute in this case. There were three points argued in the judicial review. Firstly that we had discriminated against disabled people, secondly that we had not properly dealt with a specific clinical trial, and thirdly that the appraisal was unfair because we could not give our stakeholders, including Servier access to the economic model, because it contained third party confidential information. The High Court has ruled in favor of NICE on the two grounds of discrimination and handling clinical data. Regarding the 3rd point the judge agrees that NICE was correct in not releasing "in confidence" information but nevertheless considered that, although we had asked for permission to release the information, NICE could have done more to arrange for that information to be available. NICE will now make every endeavour to encourage the owner of the information to allow us to release this information. We are pleased that the guidance issued in October 2008 remains in force for now.
Guidance documents
Implementing this guidance
We will consult on our review plans for this guidance in July 2010
About this guidance
Technology appraisals TA161
Issued: October 2008